Replies to post #24455 on Mymetics Corp (MYMX)

[bow-tie]

Antiviral properties of two trimeric recombinant gp41 proteins
www.ncbi.nlm.nih.gov › pmc › articles
Results. Two soluble trimeric recombinant gp41 proteins, termed Rgp41B and Rgp41A were designed. Both comprise the N- and C-terminal heptad repeat regions of the ectodomain of HIV-1 gp41, connected by a 7-residue hydrophilic linker, in order to mimic the trimeric fusogenic state of the transmembrane glycoprotein.

Author: Delphine Delcroix-Genête, Phenix-Lan Quan, Marie-Gaëlle Roger, Uriel Hazan, Uriel Hazan, Sébastien N...
Cited by: 5

MyMetics :: Randomized Phase I: Safety, Immunogenicity and ...
www.mymetics.com › media-center › randomized-phase-i-safety
The human immunodeficiency virus type 1 (HIV-1) is mainly transmitted through sexual contact. To infect its host, HIV-1 employs its viral membrane surface trimeric envelope glycoprotein, composed of the receptor binding domain gp120 and the membrane anchored fusion protein subunit gp41.

[bow-tie]

Acknowledgements
We would like to express our thanks to our fellow PEVIA collaborators for their great work, as well as the Innovative Medicines Initiative, the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations for their support, and for allowing this project to happen.

We also thank the Secretariat for Education, Research and Innovation (SERI) in Bern, Switzerland, which provided funding to the research group of Prof. François Spertini at the Cantonal University Hospital of Vaud and also supported the work at ExcellGene.

https://www.excellgene.com/2020/04/subunit-vaccine-production-ebola-virus-case-study/

[bow-tie]

Mymetics SA · Quality Management - ResearchGate
www.researchgate.net › profile › Mario-Amacker
Florian M Wurm Although respiratory syncytial virus (RSV) causes severe lower respiratory tract infection in infants and adults at risk, no RSV vaccine is currently available

https://www.researchgate.net/profile/Mario-Amacker

[bow-tie]

Specia - MDPI
www.mdpi.com › journal › processes
Prof. Dr. Florian M. Wurm Swiss Federal Institute of Technology Lausanne, Route Cantonale, 1015 Lausanne, Switzerland [e-mail] Dr. Martin Jordan Merck Biopharma, Biotech Process Sciences, Corsier-sur-Vevey, Switzerland [e-mail] Deadline for manuscript submissions: closed (30 April 2019) Message from the Guest Editors

essage from the Guest Editors
This Special Issue of “Transient Gene Expression for Rapid
Protein and Virus-Vector supply” focuses on protein
production and on the generation of innovative virus
vectors for the widest range of applications in R&D and for
potential use in the clinic.
We encourage submissions of papers that present various
technologies, used with CHO, HEK-293, HeLa and other
mammalian or non-mammalian derived cell lines
providing access to rapid protein synthesis and to virus
vectors. The papers should emphasize readily applicable
methods, both for “standard” laboratories, but also for
more specialized use at scales of operation that exceed the
typical research laboratory (“large scale transient gene
expression”). In spite of the fact that virus-mediated
transfer of genetic information can be considered
transient, such as with the help of Baculovirus vectors, the
editors of this Special Issue wish to restrict the issue to
submissions of “naked” DNA or RNA as carriers the genes of
interests into the host cell system

rof. Dr. Florian M. Wurm
Swiss Federal Institute of
Technology Lausanne, Route
Cantonale, 1015 Lausanne,
Switzerland
[e-mail]
Dr. Martin Jordan Merck Biopharma, Biotech
Process Sciences, Corsier-surVevey, Switzerland
[e-mail]
Deadline for manuscript
submissions:
closed (30 April 2019)


Mario Amacker
Sylvain Fleury

Recombinant PfCyRPA expressed in HEK 293 cells was chemically coupled to phosphoethanolamine and then incorporated into the membrane of unadjuvanted influenza virosomes approved as antigen delivery system for humans
https://www.researchgate.net/publication/338945184_Vaccination_with_virosomally_formulated_recombinant_CyRPA_elicits_protective_antibodies_against_Plasmodium_falciparum_parasites_in_preclinical_in_vitro_and_in_vivo_models